Shares of Glenmark Pharmaceuticals surged 14% to an all-time high on Friday after its biotechnology unit, Ichnos Glenmark ...

Motilal Oswal said the deal validates several aspects of Glenmark Pharma such as the strength of IGI's BEAT protein platform ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are ...

USFDA issued a warning letter to Glenmark Pharmaceuticals for significant CGMP violations at its Pithampur plant, including ...

AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

The licensing deal is the largest one by any Indian pharma company, and the deal value is above expectations, said Nomura.

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Glenmark Pharma shares hit upper circuit limit after signing a USD 2 billion deal with AbbVie for a cancer drug. Stock hits ...